VitaStem-Hematopoietic Stem Cell Rejuvenation

Vitastem-hematopoietic Stem Cell Rejuvenation

VitaSTEM

Aging

Unlocking longevity through in-situ Hematopoietic Stem Cell Rejuvenation using combined modulation of aging-disrupted pathways identified by publicly available and proprietary single-cell datasets from young and old human populations. Stem-cell exhaustion is a key hallmark of aging, contributing to impaired tissue repair, immune dysfunction, and systemic frailty. In this project, we took a novel approach to this challenge—rather than replacing aged blood-forming stem cells (HSCs) through transplantation, the project seeks to rejuvenate the body’s own stem cells in situ. We have analysed nearly 850,000 single-cell transcriptomes from healthy donors aged 23 to 91 from publically available and proprietary datasets, generating a high-resolution atlas of hematopoietic aging. The data reveal consistent age-related molecular signatures: younger HSCs show elevated expression of DNA repair and mitochondrial genes, while older cells exhibit ferroptosis drivers, inflammatory signaling (notably TNF and IL-17), and upregulation of CCR9 and long non-coding RNAs. These findings were confirmed in both circulating and bone marrow-derived HSCs, reinforcing their potential as biomarkers and intervention targets. In conclusion, we have identified a list of target genes, which can be used as a intervention for hematopoietic stem cell rejuvenation studies. The key insight is that we are targeting multiple aging mechanisms simultaneously - transcriptional stress responses, epigenetic regulation, and protein homeostasis. Classic damage repair thinking applied to the molecular level. This multi-pronged approach could achieve the robust rejuvenation that single interventions miss.

Description

Stem-cell exhaustion is a key hallmark of aging, contributing to impaired tissue repair, immune dysfunction, and systemic frailty. In this project, we took a novel approach to this challenge—rather than replacing aged blood-forming stem cells (HSCs) through transplantation, the project seeks to rejuvenate the body’s own stem cells in situ. We have analysed nearly 850,000 single-cell transcriptomes from healthy donors aged 23 to 91 from publically available and proprietary datasets, generating a high-resolution atlas of hematopoietic aging. The data reveal consistent age-related molecular signatures: younger HSCs show elevated expression of DNA repair and mitochondrial genes, while older cells exhibit ferroptosis drivers, inflammatory signaling (notably TNF and IL-17), and upregulation of CCR9 and long non-coding RNAs. These findings were confirmed in both circulating and bone marrow-derived HSCs, reinforcing their potential as biomarkers and intervention targets. In conclusion, we have identified a list of target genes, which can be used as a intervention for hematopoietic stem cell rejuvenation studies. The key insight is that we are targeting multiple aging mechanisms simultaneously - transcriptional stress responses, epigenetic regulation, and protein homeostasis. Classic damage repair thinking applied to the molecular level. This multi-pronged approach could achieve the robust rejuvenation that single interventions miss.

Team

Owner

Owner

Owner

Owner

Owner

Owner

Experiment Cost

$0.00

Project Score

Updated Aug 31, 2026

Technology Readiness Level

PRE-TRL

TRL 1

TRL 2

Project Progress

All updates

All categories

Timeline

Vitastem-hematopoietic Stem Cell Rejuvenation

VitaSTEM

Aging

Description

Team

Owner

Owner

Owner

Owner

Owner

Owner

Experiment Cost

$0.00

Project Score

Updated Aug 31, 2026

Technology Readiness Level

PRE-TRL

TRL 1

TRL 2

Project Progress

All updates

All categories

Timeline

Rationale

The project has completed extensive computational and bioinformatics work (~850,000 single-cell transcriptomes analyzed, AI/ML-assisted GRN modeling, differential gene expression analysis) but explicitly states that NO wet-lab experiments, binding assays, cell-based assays, or animal studies have been conducted. All experimental validation—including in vitro work with human CD34+ HSCs, in vivo models, and efficacy testing—remains planned/proposed. The absence of any empirical laboratory data firmly places this project at TRL 1 (Concept Alone).

Assessment

Low Confidence

RecommendationPROMOTE

Total Score3.75

Overall Assessment

The VitaStem HSC Rejuvenation project scores 3.75 out of 5.0 at TRL 1, reflecting a scientifically sound but early-stage concept with meaningful strengths and notable gaps. The project's strongest dimension is therapeutic relevance (score 4, weighted 2.40): the biological rationale for HSC rejuvenation is compelling, the disease mechanisms are well-characterized, and the computational foundation (~850,000 transcriptomes analyzed) is substantial for a TRL 1 project. Therapeutic optionality also scores well (score 4, weighted 0.60), given the platform's potential applicability across multiple age-related conditions and the flexibility of intervention modalities. The weakest dimension is intellectual property (score 3, weighted 0.75), where the absence of any filed patents, the use of well-known targets and publicly available datasets, and the reliance on existing compounds for key interventions create meaningful competitive and prior art risks. Overall, this is a promising early-stage project with a credible scientific foundation, but it remains entirely at the computational/hypothesis stage with no experimental validation. The project's success will hinge on whether the bioinformatically identified targets translate into measurable functional rejuvenation in wet-lab experiments, and whether a defensible IP position can be established before competitors working in this active field converge on similar targets.

Weighted Score

Therapeutic Relevance

The proposed mechanism is scientifically plausible and well-grounded. HSC aging is a biologically validated driver of immune decline, anemia, and hematologic malignancies. The project targets well-characterized aging pathways (DNA damage, epigenetic drift, mitochondrial dysfunction, inflammatory signaling) using single-cell transcriptomic data from ~850,000 transcriptomes across ages 23–91, providing a robust foundation. The identified targets (NR4A1/2, UHRF1, CD38, CCR9, etc.) are biologically relevant and supported by existing literature. However, the score is not a 5 because: (1) all evidence is computational/bioinformatic with zero experimental validation to date, (2) the multi-modal intervention strategy (targeting many genes simultaneously) adds complexity and uncertainty about which targets are truly causal vs. correlative, and (3) the heavy reliance on AI-generated hypotheses (AubrAI) without wet-lab confirmation introduces risk regarding the actual therapeutic relevance of the proposed mechanism.

Therapeutic Optionality

The concept demonstrates strong therapeutic optionality. HSC rejuvenation could address multiple therapeutic areas: age-related immune decline, anemia, myelodysplastic syndromes, leukemia prevention, chronic inflammation, and broader regenerative medicine applications. The multi-modal approach (mRNA, siRNA, small molecules, CRISPR, gene therapy) provides flexibility in intervention modality. The platform nature of the scRNA-seq/AI pipeline could potentially be applied to other stem cell types beyond HSCs. The concept also spans drug repurposing (cromolyn sodium for TPSB2) and novel drug discovery. A score of 5 is not warranted because the flexibility remains theoretical — no experimental proof that any single modality works yet, and the breadth of targets may reflect lack of focus rather than genuine optionality.

Intellectual Property

The concept has moderate IP potential. The specific combination of targets identified through their computational pipeline and the multi-modal intervention strategy could be patentable. The proprietary scRNA-seq datasets and the specific gene regulatory network models add some novelty. However, several concerns limit the score: (1) no patents have been filed or granted yet — IP filing is only listed as a future project outcome, (2) many of the individual targets (CD38, RhoA, NR4A family, rapamycin/mTOR) are well-known in the aging and hematopoiesis literature, creating significant prior art risk, (3) the use of publicly available scRNA-seq datasets means competitors could independently identify similar targets, (4) existing drugs/compounds are proposed for several targets (cromolyn sodium, fasudil, rapamycin), limiting composition-of-matter IP, and (5) the competitive landscape in HSC rejuvenation and aging biology is active with well-funded academic and industry players. The novelty may reside primarily in the specific combination and temporal coordination of interventions, which can be harder to patent and enforce.